[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332723-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332723-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-efficacy-and-safety-of-folate-receptor-targeted-antibody-drug-conjugate-therapy-in-patients-with-high-grade-epithelial-ovarian-primary-peritoneal-or-fallopian-tube-cancers-a-systematic-review-and-meta-analysis","The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers - A Systematic Review and Meta-Analysis","","Antibody-drug conjugates (ADCs) are increasingly used for recurrent ovarian cancer, and this systematic review evaluates folate receptor α (FRα)-targeted ADC therapy. The study examines treatment efficacy, treatment-related adverse events (TRAEs), and how safety outcomes relate to FRα expression levels. Prospective single-agent FRα ADC trials and combinations with chemotherapy are identified, then pooled analyses quantify objective response rate (ORR) and TRAE outcomes. Results are synthesized across included studies, with subgroup comparisons by receptor expression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-efficacy-and-safety-of-folate-receptor-targeted-antibody-drug-conjugate-therapy-in-patients-with-high-grade-epithelial-ovarian-primary-peritoneal-or-fallopian-tube-cancers-a-systematic-review-and-meta-analysis/332723/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-efficacy-and-safety-of-folate-receptor-targeted-antibody-drug-conjugate-therapy-in-patients-with-high-grade-epithelial-ovarian-primary-peritoneal-or-fallopian-tube-cancers-a-systematic-review-and-meta-analysis/332723.png","ImageObject",300,407,{"name":42,"@type":43},"Eden","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about FRα-targeted ADC therapy?","Question",{"text":63,"@type":64},"It evaluates treatment efficacy, treatment-related adverse events (TRAEs), and how safety is influenced by FRα receptor expression in patients with high-grade epithelial ovarian-related cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were trials selected and analyzed in this systematic review and meta-analysis?",{"text":68,"@type":64},"Prospective trials of single-agent FRα-targeting ADCs, and trials combining such ADCs with chemotherapy, were identified via electronic search, then pooled to analyze objective response rate (ORR) and TRAEs with subgroup comparisons by FRα expression level.",{"name":70,"@type":61,"acceptedAnswer":71},"Which ADCs are included and what overall efficacy was reported?",{"text":72,"@type":64},"Ten studies with 940 patients were included; most patients received mirvetuximab soravtansine (MIRV). The pooled ORR for the overall cohort was 37%, and the grade ≥3 adverse event incidence was 27%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332723,1790192731,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nThe Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers: A Systematic Review and Meta-Analysis  \nEun Taeg Kim1  | Ji Hyun Kim2 | Eun Young Park3 | In Hye Song4 | Han Song Park1 | Sang-Yoon Park2 | Myong Cheol Lim2,5,6  \n1Department of Obstetrics and Gynecology, Kosin University College of Medicine, Pusan, Republic of Korea | 2Center for Gynecologic Cancer, National Cancer Center, Goyang, Republic of Korea | 3Biostatistics Collaboration Team, Research Core Center, National Cancer Center, Goyang, Republic of Korea | 4Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea | 5Cancer Control and Policy,  \nNational Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea | 6Rare & Paediatric Cancer Branch and Immuno-Oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Republic of Korea Correspondence: Myong Cheol Lim ([mclim@ncc.re.kr](mclim@ncc.re.kr); [gynlim@gmail.com](gynlim@gmail.com))  \nReceived: 29 July 2024 | Revised: 11 October 2024 | Accepted: 20 October 2024  \nFunding: This work was supported by College of Medicine, Kosin University, 2024.  \nKeywords: adverse event | antibody-drug conjugate | folate receptor alpha | mirvetuximab soravtansine | ovarian cancer  \nABSTRACT  \nBackground: Antibody-drug conjugates (ADC) have emerged as a highly promising systemic option in the treatment of recurrent ovarian cancer. The present study aimed to evaluate the treatment efficacy of folate receptor α (FRα)-targeting ADCs, associated treatment-related adverse events (TRAEs), and their impact on treatment safety.  \nMethods: We conducted an electronic search to identify prospective trials of single-agent ADCs targeting FRα and those combined with chemotherapy in recurrent ovarian cancer. Information regarding the objective response rate (ORR) and TRAEs was collectively analyzed, and differences in subgroups based on FRα receptor expression levels were investigated. The protocol was registered with PROSPERO (CRD42023491151) .  \nResults: Ten studies with a total of 940 patients (859 treated with Mirvetuximab soravtansine-gynx (MIRV)), 45 with Farletuzumab Ecteribulin (MORAb-202), and 36 with Luveltamab Tazevibulin (STRO-002) were included in this meta-analysis. Based on the pooled data, the ORR of the entire cohort was 37%(95% CI: 0.30–0.43), while that of the high-FRα expression group was 34%(95% CI: 0.26–0.42). The incidence of grade ≥3 adverse events was 27%(95% CI: 0.19–0.36) .  \nConclusion: FRα-targeting ADCs, including MIRV, demonstrated definite efficacy and good safety as novel choices for secondline and beyond treatment of advanced or recurrent ovarian cancer. Patients with high FRα expression showed ORR and PFS benefits similar to those in the overall cohort.  \n\n| Eun Taeg Kim and Ji Hyun Kim contributed equally to this work as first authors. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. |\n\nCancer Medicine, 2024; 13:e70392 1 of 15  \n[https://doi.org/10.1002/cam4.70392](https://doi.org/10.1002/cam4.70392)  \n1 | Introduction  \nOvarian cancer remains one of the most lethal gynecologic malignancies, with an estimated 19,710 new cases and 13,270 deaths reported in the US in 2023 [1] . In 2020, an estimated 313,959 new cases of ovarian cancer and 207,252 ovarian cancer-related deaths were reported worldwide [2] . Epithelial ovarian cancer (EOC), which constitutes approximately 90% of malignant ovarian tumors, initially responds to cytoreductive surgery (CRS) an","cbCaigEL8IrjKgwR","https://ap.wps.com/l/cbCaigEL8IrjKgwR","pdf",2255160,15,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What question does the study address about FRα-targeted ADC therapy?\",\"answer\":\"It evaluates treatment efficacy, treatment-related adverse events (TRAEs), and how safety is influenced by FRα receptor expression in patients with high-grade epithelial ovarian-related cancers.\"},{\"question\":\"How were trials selected and analyzed in this systematic review and meta-analysis?\",\"answer\":\"Prospective trials of single-agent FRα-targeting ADCs, and trials combining such ADCs with chemotherapy, were identified via electronic search, then pooled to analyze objective response rate (ORR) and TRAEs with subgroup comparisons by FRα expression level.\"},{\"question\":\"Which ADCs are included and what overall efficacy was reported?\",\"answer\":\"Ten studies with 940 patients were included; most patients received mirvetuximab soravtansine (MIRV). The pooled ORR for the overall cohort was 37%, and the grade ≥3 adverse event incidence was 27%.\"}]","The Efficacy and Safety of Folate Receptor α-Targeted Antibody-Drug Conjugate Therapy in Patients With High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers - A Systematic Review and Meta-Analysis | PDF",1789999207,38]